Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cancer Chemistry

Abstract 2658: Anti-GD3 antibodies are targeting molecules for delivery of RNAi to melanoma

Wu W. Michael, Genevieve Pare and Victor A. Tron
Wu W. Michael
1Queen's University, Kingston, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genevieve Pare
1Queen's University, Kingston, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor A. Tron
1Queen's University, Kingston, Ontario, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-2658 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Passive non-targeted delivery of RNAi therapy into tumours has been shown to be neither very effective, nor selective in vitro and in vivo. Consequently in this study, siRNA will be linked to a drug delivery system that will express a ligand that specifically targets melanoma cells. It has been previously shown that melanoma over-expresses the cell surface ganglioside GD3, thus, the anti-GD3 R24 monoclonal antibody can function as a targeting molecule. To do so, a targeting antibody was conjugated to a coated cationic liposome (CCL) exterior to effectively deliver RNAi to melanoma. Cell surface expression of GD3 on Malme 3M, LOX IMVI and SK-MEL-5 cells was verified by flow cytometry. Internalized levels of siRNA within CCLs were the quantified via spectrometry. Encapsulation efficiency of siRNA was calculated to be greater than 70%. The quantification of antibody expression on CCLs was measured, illustrating that while non-targeted CCLs showed insignificant values of antibody as expected, antibody-conjugated CCLs presented a decreasing trend of expression that can be explained by the multi-step purification process for the final CCL products. Fluorescent microscopy results, from the combination of internalized siRNA and Tex615 RNA within CCLs, displayed greater fluorescence with antibody-conjugated CCLs than non-targeted CCLs when Malme 3M, LOX IMVI, and SK-MEL-5 cells were treated. Taken together, these results conclude that the use of GD3-targeted liposomes can promote siRNA delivery to melanoma cells.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2658.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 2658: Anti-GD3 antibodies are targeting molecules for delivery of RNAi to melanoma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 2658: Anti-GD3 antibodies are targeting molecules for delivery of RNAi to melanoma
Wu W. Michael, Genevieve Pare and Victor A. Tron
Cancer Res April 15 2010 (70) (8 Supplement) 2658; DOI: 10.1158/1538-7445.AM10-2658

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 2658: Anti-GD3 antibodies are targeting molecules for delivery of RNAi to melanoma
Wu W. Michael, Genevieve Pare and Victor A. Tron
Cancer Res April 15 2010 (70) (8 Supplement) 2658; DOI: 10.1158/1538-7445.AM10-2658
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Chemistry

  • Abstract SY01-04: High-end proteomics enables identification of breast cancer therapy resistance predictive proteins
  • Abstract SY18-02: Targeting transcriptional regulators for simultaneous modulation of p53 and NF-κB in cancer treatment
  • Abstract SY11-03: Turning enzymes on with small molecules
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Drug Delivery and Disposition

  • Abstract 2644: Advanced nanoparticles with anticancer and MRI function for liver cancer in rats and rabbits
  • Abstract 2655: Apoptotic peptide hybrid for treatment of chemotherapy-resistant cancers
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement